The additions include apps to help people better manage their sleep issues, anxiety, alcohol and opioid use disorders, and inflammatory conditions.
Evernorth, a Cigna company, has expanded its Digital Health Formulary to include five new app-based programs to help people better manage their sleep issues, anxiety, alcohol and opioid use disorders, and inflammatory conditions.
Glen Stettin, M.D.
“The latest additions give patients access to new and affordable options to improve and maintain their health while making it easier and cost-effective for our clients to include these solutions in their benefit plans,” Glen Stettin, M.D., chief innovation officer at Evernorth, said in a press release.
The five new digital solutions that have been added include:
The company said each solution on the Digital Health Formulary has been clinically reviewed and evaluated. The solutions are also evaluated for privacy, user experience, and affordability.
Plan sponsors can choose to offer individual digital solutions or incorporate them into one of Evernorth’s connected care programs, which safely integrates biometric data from the digital health solutions with pharmacy, medical, and lab data. The health apps have helped provide average savings of $120,000 per solution for health plans, according to the company.
Evernorth has also launched a series of pilot programs to evaluate the clinical impact and user experience. These include:
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More